Please select the eligibility criteria that correspond to the clinical trial below.
Title: Interventionnal and Randomized Study Measuring Virtual Reality Cue Exposure for the Relapse Prevention of Tobacco Consumption Versus Cognitive and Behavioral Approaches Therapy
Brief Summary: The therapeutic efficacy of virtual reality has been validated for the treatment of various mental disorders ,smoking behavior is the first preventable cause of death in developed countries However, after a successful withdrawal, a high relapse rate (between 40 and 70%)has been observed, which emphasize the urgent need to implement new strategies. Virtual reality cue exposure for the relapse of tobacco consumption


Options:
A: Inclusion Criteria:

* Smoking withdrawal for at least 1 week
* Age more than 18 years

Exclusion Criteria:

* Epilepsy
* Psychiatic desease
* Dementia
B: Inclusion Criteria:

* Individuals diagnosed with one or more substance use disorders (alcohol, cannabis, and or stimulant abuse/dependence) and an independent co-occurring depressive disorder (major depression or dysthymia) will be included.

Exclusion Criteria:

* Individuals with substance induced mood disorders and individuals experiencing persistent psychotic symptoms.
* Those with life threatening or unstable medical illness, neurological disorders, or inability to read will be excluded.
* Individuals currently prescribed steroids, disulfiram, or long acting benzodiazepines will be excluded.
C: Inclusion Criteria for Step 1:

* alcohol dependence according to DSM-IV criteria, with alcohol as the subject's drug of choice,
* age 18-65,
* adequate cognition and English language skills to give valid consent and complete research interviews (as assessed by the mini mental state examination),
* willingness to give written consent,
* abstinence from alcohol for between 3 and 21 days (standard clinical criteria for use of acamprosate or naltrexone),
* resolution of any clinically evident alcohol withdrawal (score 0-1 on RPA hospital alcohol withdrawal scale), and a positive score on the initial comorbidity suspicion checklist (CSC).

Exclusion Criteria for Step 1:

* sensitivity to study medications or therapy with these drugs within 6 months,
* active major psychiatric disorder associated with significant suicide risk,
* pregnancy or lactation,
* advanced liver disease (hepatocellular failure, variceal bleeding, ascites or encephalopathy),
* other serious medical illness that would interfere with adherence to the study protocol.

Entry criteria to step 2:

* Completion of 3 weeks on acamprosate and/or natlrexone and/or, resolution of any clinically evident alcohol withdrawal (score 0-1 on RPA hospital alcohol withdrawal scale),
* case formulation and diagnosis for anxiety or depression (see below).

Exclusion criteria 2:

* Non-compliance on acamprosate and/or naltrexone,
* alcohol consumption at baseline levels,
* resolution of clinically evident anxiety or depression as assessed by the case formulation (see below). These patients will be offered further treatment
D: Inclusion Criteria:

1. A current Fagerstrom scale score of 6 or greater;
2. Age 13 years old or older (Under age 18, parental consent is required);
3. Able to read and understand English.

Exclusion Criteria:

1. Have current severe, uncontrolled psychiatric disorders (i.e., acute suicidality or psychosis);
2. Have current substance dependence, other than nicotine or caffeine dependence;
3. Are in recovery for pathological gambling; or
4. Are already participating in other behavioral or medication smoking cessation programs.

Answer: A